{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05596045",
            "orgStudyIdInfo": {
                "id": "ASC10-102"
            },
            "organization": {
                "fullName": "Ascletis Pharmaceuticals Co., Ltd.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients",
            "officialTitle": "A Phase Ib, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 Tablets in Mild or Moderate COVID-19 Patients",
            "therapeuticArea": [
                "Infectious Diseases"
            ],
            "study": "study-to-evaluate-safety-tolerability-efficacy-and-pharmacokinetics-of-in-mild-to-moderate-covid-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-10",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-11-28",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-03-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2023-10-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-10-25",
            "studyFirstSubmitQcDate": "2022-10-25",
            "studyFirstPostDateStruct": {
                "date": "2022-10-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2022-10-28",
            "lastUpdatePostDateStruct": {
                "date": "2022-10-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Ascletis Pharmaceuticals Co., Ltd.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a phase Ib, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability, efficacy and pharmacokinetics of ASC10 tablets in mild or moderate COVID-19 subjects."
        },
        "conditionsModule": {
            "conditions": [
                "SARS CoV 2 Infection"
            ],
            "keywords": [
                "ASC10",
                "RdRp"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "QUADRUPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR",
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 32,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ASC10",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days",
                    "interventionNames": [
                        "Drug: ASC10"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Participants will be randomized to receive placebo",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ASC10",
                    "description": "Participants will be randomized to receive 200, 400 and 800 mg ASC10 BID for 5.5 days",
                    "armGroupLabels": [
                        "ASC10"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Participants will be randomized to receive placebo",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants with Treatment Emergent Adverse Event (TEAEs) in multiple ascending doses",
                    "timeFrame": "From Day 0 to Study Completion, up to 32 days"
                },
                {
                    "measure": "PK parameters for ASC10, GLC01-700 (molnupiravir) and ASC10-A in plasma as AUC0-12h",
                    "timeFrame": "From Day 1 to Day 6"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time (days) to sustained resolution of all targeted COVID-19 signs/symptoms",
                    "timeFrame": "From Day 1 to Study Completion, up to 32 days"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male or female subjects aged \u226518 years at screening;\n2. Those females who do not have plans for pregnancy within six months and are willing to take effective contraceptive measures from the first dose of the study drug to 3 months after the last dose;\n3. If male, agree to use adequate contraception throughout the study and for at least 3 months after the last dose of study drug;\n4. Has a documentation of PCR-confirmed SARS-CoV-2 infection with sample collection \u22645 days prior to randomization.\n\nExclusion Criteria:\n\n1. Females who are pregnant, planning to become pregnant, or breastfeeding;\n2. Has at least one characteristic or underlying medical condition associated with an increased risk of developing severe or critical illness from COVID-19;\n3. Has hypersensitivity or other contraindication to any of the components of the study interventions;\n4. Has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Handan He, Doctor",
                    "role": "CONTACT",
                    "phone": "+8657185389730",
                    "email": "handan.he@ascletis.com"
                }
            ],
            "locations": [
                {
                    "facility": "Pinnacle Research Group",
                    "city": "Anniston",
                    "state": "Alabama",
                    "zip": "36207",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 33.65983,
                        "lon": -85.83163
                    }
                },
                {
                    "facility": "Aga Clinical Trials",
                    "city": "Hialeah",
                    "state": "Florida",
                    "zip": "33012",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Roberto Aguirre",
                            "role": "CONTACT",
                            "phone": "305-819-6990",
                            "email": "RAGUIRRE@AGACLINICALTRIALS.COM"
                        }
                    ],
                    "geoPoint": {
                        "lat": 25.8576,
                        "lon": -80.27811
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000086382",
                    "term": "COVID-19"
                }
            ],
            "ancestors": [
                {
                    "id": "D000011024",
                    "term": "Pneumonia, Viral"
                },
                {
                    "id": "D000011014",
                    "term": "Pneumonia"
                },
                {
                    "id": "D000012141",
                    "term": "Respiratory Tract Infections"
                },
                {
                    "id": "D000007239",
                    "term": "Infections"
                },
                {
                    "id": "D000014777",
                    "term": "Virus Diseases"
                },
                {
                    "id": "D000018352",
                    "term": "Coronavirus Infections"
                },
                {
                    "id": "D000003333",
                    "term": "Coronaviridae Infections"
                },
                {
                    "id": "D000030341",
                    "term": "Nidovirales Infections"
                },
                {
                    "id": "D000012327",
                    "term": "RNA Virus Infections"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M2561",
                    "name": "COVID-19",
                    "asFound": "SARS-CoV-2 Infection",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13904",
                    "name": "Pneumonia",
                    "relevance": "LOW"
                },
                {
                    "id": "M13914",
                    "name": "Pneumonia, Viral",
                    "relevance": "LOW"
                },
                {
                    "id": "M14978",
                    "name": "Respiratory Tract Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M20490",
                    "name": "Coronavirus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6555",
                    "name": "Coronaviridae Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M23685",
                    "name": "Nidovirales Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M15149",
                    "name": "RNA Virus Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}